Jay M Lee MD

Summary

• Jay M. Lee, M.D., is the Surgical Director of the Thoracic Oncology Program, and Associate Professor of Surgery (Tenure Track) at the David Geffen School of Medicine at UCLA. He previously served as Chief, Division of Thoracic Surgery and Chief, Section of Thoracic Surgery for over a decade.
  He received his medical degree from UCLA and training in General Surgery at Georgetown and Duke University Medical Centers. He completed a Thoracic Research Fellowship at Memorial Sloan Kettering Cancer Center and received Thoracic Surgery training at the Brigham and Women’s Hospital and Children’s Hospital Boston at Harvard Medical School.
  Dr. Lee has published extensively in the field of thoracic oncology and has a funded research laboratory. His scientific effort has focused on translational trials involving investigator-initiated immunotherapy in human lung cancer and modulation of the immunosuppressive tumor microenvironment.
  Dr. Lee is on the Steering Committee of several neoadjuvant or perioperative immunotherapy or targeted therapy trials in resectable non-small cell lung cancer (NSCLC) including LCMC3 (atezolizumab), CANOPY-N (canakinumab and/or pembrolizumab), NAUTIKA1 (alectinib, entrectinib, vemurafenib plus cobimetinib, pralsetinib, or stereotactic body radiation therapy plus atezolizumab),and GEOMETRY-N (capmatinib). Dr. Lee is also the Study Co-Chair for the Skyscraper-15 (phase 3 trial of adjuvant atezolzumab and tiragolumab). He is on the Scientific Advisory Committee for two Phase 3 Merck trials: Perioperative MK2870 (TROP2-ADC) and Adjvuant V940 (personalized mRNA cancer vaccine) with pembrolizumab. Dr. Lee is on the Executive Committee of the LCMC4/LEADER trial to define driver mutations in early stage NSCLC. Dr. Lee is an author on numerous peri-operative clinical trials including LCMC3 and IMPower 010 (adjuvant atezolizumab).
  Dr. Lee is Board-certified by the American Board of Surgery (ABS) and the American Board of Thoracic Surgery (ABTS).